Efficacy of indapamide SR compared with enalapril in elderly hypertensive patients with type 2 diabetes. by Puig, Juan Garcia et al.
Published in: American Journal of Hypertension: Journal of the American Society of Hypertension (2007), vol. 20, iss. 1, pp. 90-97. 
Status: Postprint (Author’s version) 
 
Efficacy of Indapamide SR Compared With Enalapril in Elderly 
Hypertensive Patients With Type 2 Diabetes 
 
Juan Garcia Puig1, Michel Marre2, Franciszek Kokot3, Margarita Fernandez4, György Jermendy5, Lionel Opie6, 
Valentin Moyseev7, André Scheen8, Constantin Ionescu-Tirgoviste9, M. Helena Saldanha10, Aaron Halabe11, 
Bryan Williams12, Decio Mion Jr13, Maximino Ruiz14, Kjeld Hermansen15, Jaakko Tuomilehto16, Bartolomé 
Finizola17, Yves Gallois18, Philippe Amouyel19, Jean-Pierre Ollivier20, and Roland Asmar21
1 Hospital La Paz, Servicio de Medicina Interna, Madrid, Spain 
2 Hôpital Bichat, Service de Diabétologie et d'Endocrinologie, Paris, France 
3 Slaska Akademia Medyczna, Klinika Nefrologii, Katowice, Poland 
4 Instituto Nacional de la Nutrición 'Salvador Zubrian' Mexico, Mexico City, Mexico 
5 Bajcsy Zsilinszky Korhaz III, Budapest, Hungary 
6 Groote Schuur Hospital, Cape Heart Centre, Department of Medicine, Medical School, Cape Town, South Africa 
7 Hospital no. 64, Therapevticheski korpus, Moscow, Russian Federation 
8 CHU du Sart Tilman, Service de Diabétologie, Liège, Belgium 
9 Institute of Nutrition and Metabolic Diseases 'N. Paulescu', Bucarest, Romania 
10 HUC, Serviço de Medicina I, Coimbra, Portugal 
11 Internal Medicine Ward E, Edith Wolfson Medical Centre, Holon, Israel 
12 Department of Medicine and Therapeutics, University of Leicester, School of Medicine, Leicester, United Kingdom 
13 Centro de Estudos de Nefrologia e Hipertensao Arterial, Hospital das Clinicas, Instituto Central Cerqueira Cesar, Sao Paulo, Brazil 
14 Hospital de Clincas, Departamento de Medicina Interna, Division Diabetologia, Buenos Aires, Argentina 
15 Medicinsk afdeling C, Aarhus Amtssygehus Hospital, Aarhus, Denmark 
16 National Public Health Institute, Helsinki, Finland 
17 ASCARDIO, Barquisimeto, Estado Lara, Venezuela 
18 Centre Hospitalier Universitaire, Service de Médicine B, Angers, France 
19 U.508 INSERM, Département d'étude des lipides/lipoprotéines, Institut Pasteur de Lille, Lille, France 
20 Service de Cardiologie, Hôpital Militaire de Val-de-Grâce, Paris, France 




Background: Blood pressure control is the main influential variable in reducing microalbuminuria in patients 
with type 2 diabetes. In this subanalysis of the Natrilix SR versus Enalapril Study in hypertensive Type 2 
diabetics with micrOalbuminuRia (NESTOR) study, we have compared the effectiveness of indapamide 
sustained release (SR) and enalapril in reducing blood pressure and microalbuminuria in patients ≥65 years of 
age. 
Methods: Of the 570 hypertensive patients with type 2 diabetes and persistent microalbuminuria in the 
NESTOR study, 187 (33%) individuals ≥65 years of age were included in this analysis. Of these, 95 patients 
received indapamide SR 1.5 mg and 92 patients received enalapril 10 mg, taken once daily in both cases. 
Adjunctive amlodipine and/or atenolol was added if required. 
Results: The urinary albumin-to-creatinine ratio decreased by 46% in the indapamide SR group and 47% in the 
enalapril group. Noninferiority of indapamide SR over enalapril was demonstrated (P = .0236; 35% limit of 
noninferiority) with a ratio of 0.95 (95% CI: 0.68, 1.34). Mean arterial pressure decreased by 18 mm Hg and 15 
mm Hg in the indapamide SR and the enalapril groups, respectively (P = .1136). The effects of both treatments 
seen in these elderly patients were similar to those observed in the main population, although the extent of the 
reduction in microalbuminuria was slightly higher. Both treatments were well tolerated, and no difference 
between groups was observed regarding glucose or lipid profiles. 
Conclusion: Indapamide SR is not less effective than enalapril in reducing microalbuminuria and blood pressure 
in patients aged >65 years of age with type 2 diabetes and hypertension. Am J Hypertens 2007;20: 90-97 
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The prevalence of type 2 diabetes is increasing worldwide.1 This is of particular concern, as the disease is 
associated with significant morbidity and mortality, particularly in terms of the increased risk of premature death 
from coronary heart disease, peripheral vascular disease or stroke.2 Hypertension and diabetes are interlinked, as 
hypertension is observed in up to 75% of patients with type 2 diabetes,3 and patients with elevated blood 
pressure (BP) being significantly more likely to develop type 2 diabetes.4 Patients with hypertension and 
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diabetes also frequently present with microalbuminuria,5 which increases cardiovascular risk still further.6 
Microalbuminuria is recognized as a strong and early predictor for the development of diabetic renal diseases 
(including end-stage renal disease),7,8 and is itself associated with an increased risk of morbidity and mortality 
from cardiovascular disease.9 
The angiotensin-converting enzyme inhibitors (ACEI) are known to decrease proteinuria and to preserve 
glomerular filtration rate (GFR) in patients with diabetes,10,11 but little is known about the effects of diuretic 
therapy on microalbuminuria in diabetic patients. The Natrilix SR versus enalapril study in hypertensive type 2 
diabetics with microalbuminuria (NESTOR) set out to compare the effectiveness of two antihypertensive drugs: 
an ACEI, enalapril, and a diuretic, indapamide sustained release (SR)12 with opposite effects on the renin-
angiotensin system (RAS) in reducing microalbuminuria.13 Results of the study suggested that indapamide SR 
and enalapril reduced microalbuminuria to a similar extent, with equivalent mean BP control. 
The risks of developing type 2 diabetes and hypertension increase with advancing age,14 and thus elderly patients 
presenting with both type 2 diabetes and hypertension are a growing population. It is well known, however, that 
elderly patients represent a difficult population to treat effectively with antihypertensive therapy, particularly 
those with isolated systolic hypertension (ISH).15 In addition, renal function tends to decline with advancing 
age.16 
The NESTOR study included patients up to the age of 80 years. This article therefore describes a subgroup 
analysis of the NESTOR study, evaluating the impact of indapamide SR or enalapril on microalbuminuria and 




The design of this study has previously been published.13 Briefly, NESTOR was a double-blind, double-dummy, 
two-parallel groups, randomized, multicenter, international, 1-year study. It compared indapamide SR with 
enalapril in patients with type 2 diabetes and hypertension. After an initial 4-week placebo run-in period, during 
which previous antihypertensive therapy was withdrawn, patients were randomized to receive either indapamide 
SR 1.5 mg or enalapril 10 mg once daily for 1 year. From week 6 of treatment, additional open-label 
antihypertensive treatment was administered in a stepwise manner to achieve target BP levels (systolic BP [SBP] 
≤140 mm Hg and diastolic BP [DBP] <85 mm Hg). Additional antihypertensive treatment (if required) consisted 
of amlodipine 5 mg once daily, then amlodipine 10 mg once daily, then amlodipine 10 mg once daily plus 
atenolol 50 mg once daily, then amlodipine 10 mg plus atenolol 100 mg once daily, with each step separated by 
6-week intervals. Modification of antidiabetic treatment was allowed as necessary, including the use of insulin. 
The use of potassium supplements was allowed if kalemia was <3.5 mmol/L. The study was performed in 
accordance with Good Clinical Practice and approved by Ethics committees in each country. Each patient gave 
his or her written informed consent before enrollment. 
Study Population 
As previously described,13 patients were recruited at 231 centers in 18 countries. The main criteria for inclusion 
were men and women aged 35 to 80 years, with type 2 diabetes (controlled by diet with or without one or more 
oral antidiabetic medications unchanged for at least 3 months), persistent microalbuminuria (an albumin 
excretion rate [AER] of 20 to 200 µg/min in at least two of three overnight urine samples collected during the 
run-in placebo period) and essential hypertension (SBP 140 to 180 mm Hg and DBP <110 mm Hg). Main 
criteria for exclusion were severe hypertension, body mass index >40 kg/m2, hematuria, or leucocyturia, and 
urinary tract infection. This subanalysis includes data only from patients who were eligible for the double-blind 
phase of the study and who were ≥65 years of age. 
Efficacy Evaluations 
The primary efficacy evaluation was comparison of albuminuria after treatment with indapamide SR or enalapril, 
as previously described.13 During the run-in period and at weeks 12, 24, 36, and 52, urine samples were collected 
overnight for measurement of albumin using nephelometry (assay sensitivity 2 mg/L), and for measurement of 
creatinine using the Jaffe method. Creatinine clearance was estimated with the Cockroft formula.17 Results were 
expressed as urinary albumin-to-creatinine ratio (UACR), AER, and fractional albumin clearance, with baseline 
values being defined as the median of values determined from the three urine samples collected during the 
placebo run-in period. Secondary efficacy evaluations included changes in SBP and DBP, which were evaluated 
at weeks 6, 12, 18, 24, 36, and 52, as the mean of three measurements in the supine position using a mercury 
sphygmomanometer with a cuff sized to the patient's arm as recommended. Mean arterial pressure (MAP) was 
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therefore calculated as one third of SBP plus two thirds of DBP. In addition, alterations in biochemical 
parameters from baseline to the end of the study were evaluated. 
Acceptability Evaluations 
Assessment of acceptability was based mainly on an analysis of adverse events reported during the study, ECG 
parameters, body mass index, and biochemical parameters. 
Statistical Analyses 
Statistical analyses were conducted on the full analysis set population, defined as all randomized patients having 
received at least one therapeutic unit and having at least one evaluation of microalbuminuria available at baseline 
(placebo run-in) and after treatment. The main objective of the analysis was to test the hypothesis of one-sided 
equivalence (noninferiority) of indapamide SR compared with enalapril on microalbuminuria reduction, and 
similar BP level.18 Safety was evaluated for all randomized patients who received at least one therapeutic unit. 
Details of the statistical analyses are described in the main study publication.13 Briefly, the analysis of 
microalbuminuria was performed on log-transformed values. The between-treatment difference (indapamide SR 
- enalapril) of adjusted means was analysed by a one-sided noncentral Student t test. A limit of noninferiority 
that was less than 35% of the value in the enalapril group at the final visit was used, this being the assumed 
clinically significant difference.13 The results were expressed as a ratio of geometric means with an associated 
95% confidence interval. All analyses were adjusted on baseline value for each parameter. 
 
RESULTS 
Demographic and Baseline  Characteristics of Patients 
Of the 570 patients enrolled in NESTOR, 187 (33%) were >65 years of age. Of these patients, 95 received 
indapamide SR and 92 received enalapril. 
Patient demographics and baseline characteristics were similar between groups as shown in Table 1, although 
there were significantly more men in the indapamide SR group. 
Of the 187 patients, 15 patients (10 in the indapamide SR group and five in the enalapril group) withdrew from 
the study. Ten of these withdrawals were for reason of adverse events; three for a major protocol deviation; one 
for lack of efficacy; and one for a nonmedical reason. The mean compliance with treatments throughout the 
duration of the study was similar in the two groups: 80% in the indapamide SR group and 84% in the enalapril 
group. 
From week 6 of study treatment, one or more adjunctive therapies for hypertension (ie, amlodipine, atenolol, or 
both) were taken by 78 (42%) patients; 40 (42%) in the indapamide SR group and 38 (41%) in the enalapril 
group. 
 
Table 1.   Demographic and baseline characteristics of patients ≥65 years of age randomized in the NESTOR 
study 
Demographics (full analysis set) IND SR (n = 95) ENL (n = 92) P value 
Age, years (SD) 71.1 (4.2) 70.0 (4.1) .072 
Men/women (%) 72/28 58/42 .046 
White/African American/Asian/other (%) 92/3/1/4 92/2/1/4 .982 
Body mass index; kg/m2 (SD) 27.9 (3.7) 28.9 (4.1) .081 
Smoker/ex-smoker/non-smoker (%) 15/27/58 14/32/54 .823 
Diabetes duration; months (SD) 129 (102) 135 (99) .684 
Family history of diabetes (%) 34 43 .169 
≥One oral hypoglycaemic agent (%)   .779 
   Sulphonamides, urea derivatives 65 84  
   Biguanides 43 46  
HbA1c; mean % (SD) 7.5 (1.9) 7.6 (1.7) .713 
Hypertension duration, months (SD) 132 (102) 108 (93) .095 
Family history of hypertension (%) 25 36 .115 
Hypertension previously treated (%) 80 72 .187 
ENL = enalapril; HbA1c = glycosylated hemoglobin; IND SR = indapamide SR; NESTOR = Natrilix SR versus Enalapril Study in 
hypertensive Type 2 diabetics with micrOalbuminuRia. 
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Table 2.   Microalbuminuria and renal function evaluations at baseline and endpoint 
Criteria IND SR (n = 95) ENL (n = 92) Intergroup comparison 
mean (95% CI) 
P value 
UACR (mg/mmol)     
   Baseline* Gmean (Q1, Q3) 6.8 (3.7, 12.0) 8.5 (4.9, 12.9)   
   Final Gmean (Q1, Q3) 3.7 (1.8, 9.0) 4.5 (1.6, 10.4) 0.95 (0.68; 1.34) .0236† 
   % Decline Gmean (95% CI) 46 (31; 57) 47 (32; 59)   
AER (µg/min)      
   Baseline* Gmean (Q1, Q3) 55.9 (34.5, 94.9) 65.6 (39.4, 114.5)   
   Final Gmean (Q1, Q3) 31.6 (12.3, 89.7) 35.5 (14.0, 83.4) 1.00 (0.69; 1.45) .0579† 
   % Decline Gmean (95% CI) 43 (27; 56) 46 (28; 59)   
Creatinine clearance (mL/min)     
   Baseline‡ Mean (SD) 70.5 (18.6) 70.2 (19.0)   
   Final Mean (SD) 66.4 (17.5) 67.3 (18.8)   
   ∆ Decrease Mean (95% CI) -4.1 (-5.5; -2.7) -2.9 (-4.6; -1.3) -1.09 (-3.12; 0.94) .2904§ 
Fractional albumin clearance (10-6)     
   Baseline* Gmean (Q1, Q3) 12.7 (7.6, 21.9) 16.3 (9.5, 26.1)   
   Final Gmean (Q1, Q3) 7.4 (3.5, 19.1) 9.2 (3.1, 23.0) 0.94 (0.67; 1.34) .223† 
   % Decline Gmean (95% Cl) 43 (27; 55) 44 (27; 57)   
AER = albumin excretion rate; Cl = confidence interval; ENL = enalapril; Gmean = geometric mean; IND SR = indapamide sustained 
release; Q1 = first quartile; Q3 = third quartile; UACR = urinary albumin : creatinine ratio. 
Within-group variations in microalbuminuria are expressed as % decline; within-group variations in blood pressure and creatinine clearance 
are expressed as ∆ decrease. 
* Baseline: median of the three first clean and valid values of V1, V2, V3; † P value for noninferiority testing; ‡ Baseline value is calculated 
only for patients with final value; § P value for difference testing. 
 
Table 3.   Supine blood pressure (mm Hg) evaluations at baseline and endpoint 




SBP      
   Baseline Mean (SD) 165 (10) 165 (9)   
   Final Mean (SD) 138 (10) 141 (15)   
   ∆ Decrease Mean (95% CI) -27 (-29 to -24) -23 (-26 to -20) -3 (-7 to 0.5) .0885 
DBP      
   Baseline Mean (SD) 93 (8) 92 (7)   
   Final Mean (SD) 79 (8) 81 (8)   
   ∆ Decrease Mean (95% CI) -13 (-15 to -11) -11 (-13 to -10) -1 (-3 to 1) .2527 
MAP      
   Baseline Mean (SD) 117 (7) 116 (6)   
   Final Mean (SD) 99 (7) 101 (10)   
   ∆ Decrease Mean (95% CI) -18 (-20 to -16) -15 (-17 to -13) -2 (-4 to 0.5) .1136 
DBP = diastolic blood pressure; MAP = mean arterial pressure; SBP = systolic blood pressure. 
Analyses are adjusted on baseline. Intergroup comparison = IND SR - ENL. P values are for difference testing. 
 
Microalbuminuria and Renal Function 
Overall, there was a significant decrease in UACR of 46% (95% confidence interval [CI]: 31, 57) in the 
indapamide SR group and 47% (95% CI: 32, 59) in the enalapril group (Table 2). The noninferiority of 
indapamide SR to enalapril was statistically demonstrated (P = .0236) in reducing UACR with a ratio of 0.95 
(95% CI: 0.68, 1.34). At the end of the study, the UACR was normal (<2.5 mg/mmol in men and <3.5 mg/mmol 
in women) in 41/95 (43%) and 34/92 (37%) of patients in the indapamide SR and enalapril groups, respectively 
(P = .387). 
The results of the microalbuminuria evaluations are shown in Table 2. Renal function, as measured by creatinine 
clearance showed a statistically decrease from baseline to the end of the study in both treatment group but the 
difference in decrease between the two groups was not significant (Table 2). A sensitivity analysis including 
only those patients who completed the study without major protocol violations indicated that the results were of 
the same order (for UACR, AER, and FAC), but there were no statistically significant differences because of the 
lack of power associated with the lower patient numbers involved (77 receiving indapamide SR and 83 
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Both treatments showed antihypertensive efficacy as illustrated in Table 3. A total of 87% of patients receiving 
indapamide SR and 77% of patients receiving enalapril reached target BP as defined by the protocol (P = .068). 
There were no significant differences between groups in the magnitude of the reductions from baseline to 
endpoint in SBP, DBP or MAP with differences of 3 mm Hg, 1 mm Hg, and 2 mm Hg in favor of indapamide 
SR, respectively. 
Acceptability 
The two treatment regimens were generally well tolerated over the 1-year follow up and the frequency of adverse 
events was similar in both groups. No orthostatic hypotension was reported. Adverse events were generally 
consistent with the known pharmacological properties of both products (kalemia changes for both indapamide 
SR [decrease] and enalapril [increase] and cough for the ACE inhibitor). Three patients (3.2%) in the 
indapamide SR group and two patients (2.2%) in the enalapril group reported at least one emergent adverse 
event considered to be related to treatment (dizziness, cough, and constipation in the indapamide SR group, and 
hyperuricemia and aggravated hypertension in the enalapril group). 
Assessments of plasma biochemistry parameters at baseline and endpoint are presented in Table 4. Lipid profiles 
(total cholesterol, HDL, LDL, triglycerides), fasting plasma glucose, and HbAlc did not show any difference 
between the two groups. Among all biochemical parameters examined during the study, a difference between 
groups was only observed for serum potassium and uric acid (expected). Hepatic and renal functions appeared to 
be well preserved. 
 
Table 4.   Change in biochemistry parameters during the study 
IND SR (n = 95) ENL (n = 92)  





Na+ , mmol/L (SD) 140.4 (2.0) 139.3 (2.4) 140.0 (2.3) 139.1 (2.1) -0.01 .9816 
K+, mmol/L (SD) 4.4 (0.4) 4.2 (0.5) 4.5 (0.4) 4.6 (0.4) -0.34 .0000 
Uric acid, µmol/L (SD) 338.6 (82.7) 374.9 (92.8) 334.7 (85.1) 348.1 (97.4) 23.82 .0227 
Total chol., mmol/L (SD) 5.2 (0.9) 5.3 (1.0) 5.3 (1.1) 5.2 (1.2) 0.14 .2044 
HDL chol., mmol/L (SD) 1.1 (0.3) 1.2 (0.3) 1.2 (0.4) 1.2 (0.3) 0.01 .7761 
LDL chol., mmol/L (SD) 3.3 (0.7) 3.4 (0.9) 3.3 (0.9) 3.2 (1.0) 0.13 .1577 
Triglycerides, mmol/L (SD) 1.6 (0.9) 1.7 (0.9) 1.7 (0.9) 1.8 (0.9) -0.05 .6566 
Glucose, mmol/L (SD)† 8.7 (3.2) 9.2 (3.7) 9.3 (3.4) 9.4 (3.0) 0.10 .8103 
HbA1c, % (SD) 7.5 (1.9) 8.0 (1.9) 7.6 (1.7) 7.9 (1.8) 0.19 .3177 
chol. = cholesterol; ENL = enalapril; HDL = high-density lipoproteins; IND SR = indapamide sustained release; K = plasma potassium; LDL 
= low-density lipoprotein; Na = plasma sodium. * Intergroup comparison of changes adjusted on baseline; † Fasting plasma glucose (P 
values are for difference testing). 
 
DISCUSSION 
In this analysis of the elderly (age 65 to 80 years) subset of hypertensive patients with type 2 diabetes from the 
NESTOR study, it was found that microalbminuria was generally reduced by a similar extent in the indapamide 
SR and enalapril groups as evaluated by changes from baseline to endpoint in UACR, AER, and fractional 
albumin clearance. These are the first published data evaluating the long-term (1-year) impact of diuretic 
antihypertensive therapy on microalbuminuria in elderly hypertensive patients with type 2 diabetes. In 
hypertensive patients with type 2 diabetes who also have nephropathy, the Diabetics Exposed to Telmisartan and 
enalaprIL (DETAIL) study has most recently shown that long-term (5-year) treatment with enalapril or the 
angiotensin receptor blocker telmisartan results in small overall changes in urinary albumin excretion, suggestive 
of a renoprotective effect.19 
Overall, the benefits of both treatments on microalbuminuria seen in this elderly subset of NESTOR patients are 
similar to those observed in the overall NESTOR population, although the extent of the reduction in mi-
croalbuminuria was generally slightly higher here than observed in the main study. This may be attributed to the 
fact that the baseline albumin levels in the elderly population were slightly higher, possibly indicative of a higher 
degree of renal damage in the elderly population, as would be anticipated based on the difference in age. Indeed, 
the baseline creatinine clearance observed in the elderly population was lower than in the overall population (in 
which values of 91.5 mL/min were seen in the indapamide SR group and 93.4 mL/min in the enalapril group at 
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baseline), supporting this suggestion. 
Modulation of the RAS (using ACEI or angiotensin receptor blockers) has been shown to provide effective BP 
control in elderly hypertensive patients, as has diuretic therapy. The seventh report of the Joint National 
Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7) recommends 
thiazide-type diuretics as the preferred initial antihypertensive agent, noting that they have been "virtually 
unsurpassed" in preventing the cardiovascular complications of hypertension and that low-dose diuretics are 
generally well tolerated.20 However, the benefits of different antihypertensive treatments in elderly hypertensive 
patients who also have type 2 diabetes are less well characterized. In this sub-study, BP was decreased by both 
indapamide SR and enalapril. Reductions in MAP (which reflects the BP at the glomerular level of the kidney) 
were similar between groups, which may support the suggestion that the similar reductions in microalbuminuria 
seen were as a result of similar antihypertensive effects of the two agents. With regard to the mean supine SBP, 
this fell below target levels (<140 mm Hg) only in the indapamide SR group. This was not a statistically 
significant difference in the elderly subgroup, probably because of size effect, although the greater reductions in 
supine SBP seen with indapamide SR compared with enalapril in the overall NESTOR population were 
significant. Combination therapy is often required to achieve effective BP control in the elderly, but in this 1-
year study, less than 45% of patients in either group required combination therapy. 
Overall, these results indicate that the proposed predominant role of high systemic BP in the development of 
microalbuminuria in hypertensive patients with type 2 diabetes noted in the overall NESTOR population 
continues to apply when elderly patients are considered. The National Kidney Foundation note that increased 
excretion of albumin is a sensitive marker for chronic kidney disease because of diabetes, hypertension, or 
glomerular disease,21 with microalbuminuria progressing to overt proteinuria in 20% to 40% of patients with type 
2 diabetes.8,22 
Although data in elderly hypertensive patients with type 2 diabetes are limited, the Systolic Hypertension in the 
Elderly Program (SHEP) and the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial 
(ALLHAT) included large elderly diabetic populations. The SHEP study included only patients with isolated 
systolic hypertension (ISH); however, JNC 7 notes that by age 60 years, about two thirds of individuals with 
hypertension have ISH20; hence a large proportion of patients in the NESTOR elderly population are likely to 
have had this diagnosis. High BP was associated with reduced kidney function in SHEP, which involved 4736 
hypertensive men and women >65 years of age. This study suggested that the incidence and relative risk of a 
decline in kidney function increased at higher levels of BP, mainly SBP, independent of age, sex, ethnicity, 
smoking, diabetes, and history of cardiovascular disease.23 In SHEP, low-dose diuretic-based therapy was found 
to be effective compared with placebo in preventing cardiovascular complications in elderly patients with type 2 
diabetes mellitus and isolated systolic hypertension.24 In ALLHAT, which involved 33,357 participants aged ≥55 
years with hypertension and at least one other coronary heart disease risk factor (diabetes in some patients), 
thiazide-type diuretics were found to be superior in preventing one or more major forms of cardiovascular 
disease compared with amlodipine or lisinopril.25 
Microalbuminuria has been related to other "surrogate markers" of high cardiovascular risk such as left 
ventricular hypertrophy, independent of BP.26 The reductions in microalbuminuria seen in this study are 
therefore consistent with the reductions in left ventricular mass index seen in various studies of indapamide SR 
and enalapril. However, in the 1-year left ventricular hypertrophy regression, indapamide versus enalapril 
(LIVE) study, indapamide SR was found to be significantly more effective than enalapril at reducing left 
ventricular mass index.27 
Both indapamide SR and enalapril treatment were well tolerated in this study, and no new adverse events 
occurred. However, there were two unexpected adverse events, in that cough is not usually related to diuretic 
use, and hyperuricaemia is not typically associated with ACEI use. These results have been checked and 
confirmed as correct, and should be explained by the double-blind situation. The acceptability of treatment was 
similar to that observed in the main NESTOR study, which is noteworthy because concomitant diseases are more 
common in the elderly and polypharmacy is more frequently seen. For plasma potassium concentration, the 
difference observed between the indapamide SR and enalapril groups is consistent with previous findings 
showing that ACEI increase potassium concentrations and diuretics decrease them. In relation to cardiovascular 
risk, it is reassuring that neither treatment had a significant effect on other parameters associated with 
cardiovascular morbidity and mortality such as HDL cholesterol, LDL cholesterol and triglycerides. There were 
also no significant differences between the groups in terms of glucose or HbAlc, although it should be noted that 
choice of diabetic therapy was largely at the investigators discretion, and thus the impact of antihypertensive 
treatment on these two parameters cannot be clearly evaluated. Although these biochemical parameters were 
evaluated only at the beginning and end of the study, more intensive evaluation of such parameters supports the 
metabolic neutrality of indapamide SR therapy during long-term treatment in at-risk hypertensive patients at risk, 
including those with diabetes and those who are elderly.28,29 The limited impact of enalapril on lipid parameters 
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has also been previously observed.30 
In conclusion, indapamide SR was not less effective than enalapril in reducing microalbuminuria and BP in 
elderly hypertensive patients with type 2 diabetes, consistent with the use of indapamide SR as first-line 
antihypertensive treatment in this patient population. 
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